All In Biotech

Drug Trial Radar · NCT00000766

CMV Retinitis Retreatment Trial

Last checked: Nov 19, 2026Latest source record: Mar 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

300

Actual

Start

Not stated

Primary completion

Sep 1995

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and efficacy of three therapeutic regimens (foscarnet, ganciclovir, or the combination) for recurrent or persistent AIDS-related cytomegalovirus (CMV) retinitis. Although therapy with foscarnet or ganciclovir halts retinitis progression in 90 percent of patients treated, relapses are common and may accelerate due to development of drug resistance, deteriorating immune function, or other factors. Treatment strategies currently being investigated include switching patients from one drug to the other or combining the two drugs.

Conditions

  • Cytomegalovirus Retinitis
  • HIV Infections

Interventions

  • Foscarnet sodiumDrug

  • GanciclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCSD - Shiley Eye Ctr / SOCA

    La Jolla, California

  • UCLA - Jules Stein Eye Institute / SOCA

    Los Angeles, California

  • UCSF - San Francisco Gen Hosp

    San Francisco, California

  • Northwestern Univ / SOCA

    Chicago, Illinois

  • Johns Hopkins Hosp / SOCA

    Baltimore, Maryland

  • New York Univ Med Ctr / SOCA

    New York, New York

  • New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA

    New York, New York

  • Mount Sinai Med Ctr / SOCA

    New York, New York

  • Univ of North Carolina / SOCA

    Chapel Hill, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.